CU24133B1 - Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5 - Google Patents

Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5

Info

Publication number
CU24133B1
CU24133B1 CU20120116A CU20120116A CU24133B1 CU 24133 B1 CU24133 B1 CU 24133B1 CU 20120116 A CU20120116 A CU 20120116A CU 20120116 A CU20120116 A CU 20120116A CU 24133 B1 CU24133 B1 CU 24133B1
Authority
CU
Cuba
Prior art keywords
polipeptides
monomers
diseases
link
human
Prior art date
Application number
CU20120116A
Other languages
English (en)
Spanish (es)
Other versions
CU20120116A7 (es
Inventor
Karen Cromie
Bruno Dombrecht
Seth Ettenberg
Joost Kolkman
Jing Li
Kris Meerschaert
David Raymond Stover
Jingxin Zhang
Original Assignee
Novartis Ag
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43877025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24133(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Ablynx Nv filed Critical Novartis Ag
Publication of CU20120116A7 publication Critical patent/CU20120116A7/es
Publication of CU24133B1 publication Critical patent/CU24133B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
CU20120116A 2010-02-10 2011-02-10 Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5 CU24133B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30317310P 2010-02-10 2010-02-10
US30859910P 2010-02-26 2010-02-26
PCT/EP2011/051958 WO2011098520A1 (en) 2010-02-10 2011-02-10 Agonist dr5 binding polypeptides

Publications (2)

Publication Number Publication Date
CU20120116A7 CU20120116A7 (es) 2014-02-28
CU24133B1 true CU24133B1 (es) 2015-11-27

Family

ID=43877025

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20120116A CU24133B1 (es) 2010-02-10 2011-02-10 Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5

Country Status (31)

Country Link
US (2) US9120855B2 (OSRAM)
EP (1) EP2534176A1 (OSRAM)
JP (1) JP2013519364A (OSRAM)
KR (1) KR20130031241A (OSRAM)
CN (1) CN102884083A (OSRAM)
AR (1) AR080158A1 (OSRAM)
AU (1) AU2011214355B2 (OSRAM)
BR (1) BR112012019924A2 (OSRAM)
CA (1) CA2789251A1 (OSRAM)
CL (1) CL2012002217A1 (OSRAM)
CO (1) CO6561836A2 (OSRAM)
CR (1) CR20120415A (OSRAM)
CU (1) CU24133B1 (OSRAM)
EA (1) EA201201114A1 (OSRAM)
GE (1) GEP20146176B (OSRAM)
GT (1) GT201200236A (OSRAM)
IL (1) IL221289A0 (OSRAM)
MA (1) MA34053B1 (OSRAM)
MX (1) MX2012009328A (OSRAM)
MY (1) MY156337A (OSRAM)
NI (1) NI201200134A (OSRAM)
NZ (1) NZ601582A (OSRAM)
PE (1) PE20121703A1 (OSRAM)
PH (1) PH12012501613A1 (OSRAM)
SG (1) SG183210A1 (OSRAM)
TN (1) TN2012000393A1 (OSRAM)
TW (1) TWI480051B (OSRAM)
UA (1) UA106900C2 (OSRAM)
UY (1) UY33222A (OSRAM)
WO (1) WO2011098520A1 (OSRAM)
ZA (1) ZA201205864B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2644678C1 (ru) 2010-10-29 2018-02-13 Дайити Санкио Компани, Лимитед Новое антитело против dr5
GB201118359D0 (en) 2011-10-25 2011-12-07 Univ Sheffield Pulmonary hypertension
HK1206760A1 (en) * 2012-03-28 2016-01-15 Amgen Inc. Dr5 receptor agonist combinations
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2015100409A2 (en) * 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
WO2015104994A1 (ja) 2014-01-10 2015-07-16 学校法人帝京平成大学 組換え偏性嫌気性グラム陽性菌
SG11201706024YA (en) * 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
CN104826121A (zh) * 2015-02-11 2015-08-12 嘉兴学院 肿瘤靶向基因递送系统及其应用
PL3322734T3 (pl) * 2015-07-16 2021-05-04 Inhibrx, Inc. Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5
KR102791773B1 (ko) * 2015-10-30 2025-04-03 갤럭시 바이오테크, 엘엘씨 사멸 수용체 4 및 사멸 수용체 5에 결합하는 매우 강력한 항체
NO2768984T3 (OSRAM) 2015-11-12 2018-06-09
KR101926834B1 (ko) 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
KR20200080304A (ko) * 2017-11-13 2020-07-06 크레센도 바이오로직스 리미티드 Cd137에 결합하는 단일 도메인 항체
US20190234933A1 (en) * 2018-02-01 2019-08-01 Genadam Therapeutics, Inc. Compositions and assays
CN117285643A (zh) 2022-06-16 2023-12-26 清华大学 一种相变调节套件及其用途
WO2024013315A1 (en) 2022-07-15 2024-01-18 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
WO2024153050A1 (zh) * 2023-01-17 2024-07-25 苏州永心生物科技有限公司 Dr5结构域变体及其应用
AU2024308381A1 (en) * 2023-06-29 2025-11-20 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
WO2025206402A1 (ja) * 2024-03-29 2025-10-02 株式会社沖縄Ｕｋａｍｉ養蚕 アフリカ豚熱ワクチン産生組換えエリ蚕及びその利用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
AU675223B2 (en) 1992-05-08 1997-01-30 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
WO1994002610A1 (en) 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
ES2155854T3 (es) 1993-06-09 2001-06-01 Unilever Nv Procedimiento de produccion de proteinas de fusion que comprende fragmentos de scfv con la ayuda de un molde transformado.
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU7298398A (en) 1996-11-19 1998-06-10 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
CN1316910A (zh) 1998-02-19 2001-10-10 埃克斯西特治疗公司 用于调节淋巴细胞活化的组合物及方法
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1425694A2 (en) 2001-08-03 2004-06-09 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
WO2003025020A1 (en) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Method of constructing camel antibody library
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
US20050037358A1 (en) 2001-12-21 2005-02-17 Serge Muyldermans Method for cloning of variable domain sequences
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
AU2003286002B2 (en) 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
KR20090046973A (ko) 2002-11-27 2009-05-11 아이알엠 엘엘씨 암세포에서 세포자멸사를 유도하기 위한 방법 및 조성물
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
WO2005018629A1 (en) 2003-08-12 2005-03-03 Yarbrough William M Treatment for acne vulgaris and method of use
ES2385829T3 (es) 2003-08-20 2012-08-01 Ucb Pharma, S.A. Métodos para obtener anticuerpos
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
WO2005114187A2 (en) 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
WO2005122741A2 (en) 2004-06-21 2005-12-29 Washington University Antibodies against west nile virus and therapeutic and prophylactic uses thereof
US20060008601A1 (en) 2004-06-25 2006-01-12 Zeik Douglas B Flexible laminate having an integrated pressure release valve
CA2580336C (en) 2004-07-22 2016-07-19 Roger Kingdon Craig Vh heavy chain only antibodies, and vh heavy chain only dimer compounds and uses thereof
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP5113523B2 (ja) 2004-10-13 2013-01-09 アブリンクス ナームローゼ フェンノートシャップ アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006079372A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
GB2424983A (en) 2005-04-07 2006-10-11 Autoliv Dev Seatbelt pretensioner control system
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
BRPI0609797B8 (pt) 2005-05-20 2021-05-25 Ablynx Nv nanocorpos melhorados para o tratamento de desordens mediadas por agregação
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
WO2007118670A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. Dp-78-like nanobodies
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2086998B1 (en) 2006-10-11 2011-12-07 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
JP5302519B2 (ja) 2007-08-03 2013-10-02 倉敷紡績株式会社 ヒトパピローマウイルスを検出するためのプライマーセット及びプローブ
AU2007358569B2 (en) 2007-09-07 2014-09-04 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽

Also Published As

Publication number Publication date
NZ601582A (en) 2014-07-25
CL2012002217A1 (es) 2014-01-31
MY156337A (en) 2016-02-15
TW201130513A (en) 2011-09-16
US20110318366A1 (en) 2011-12-29
CU20120116A7 (es) 2014-02-28
UA106900C2 (uk) 2014-10-27
EP2534176A1 (en) 2012-12-19
GT201200236A (es) 2015-05-20
PH12012501613A1 (en) 2012-10-22
AU2011214355B2 (en) 2014-05-22
US9120855B2 (en) 2015-09-01
WO2011098520A1 (en) 2011-08-18
IL221289A0 (en) 2012-10-31
TN2012000393A1 (en) 2014-01-30
AU2011214355A1 (en) 2012-08-30
ZA201205864B (en) 2013-05-29
GEP20146176B (en) 2014-10-10
SG183210A1 (en) 2012-09-27
MX2012009328A (es) 2012-11-30
PE20121703A1 (es) 2012-12-11
BR112012019924A2 (pt) 2017-05-02
TWI480051B (zh) 2015-04-11
CR20120415A (es) 2013-01-09
KR20130031241A (ko) 2013-03-28
MA34053B1 (fr) 2013-03-05
AR080158A1 (es) 2012-03-21
CO6561836A2 (es) 2012-11-15
CN102884083A (zh) 2013-01-16
CA2789251A1 (en) 2011-08-18
EA201201114A1 (ru) 2013-03-29
UY33222A (es) 2011-09-30
US20150259426A1 (en) 2015-09-17
JP2013519364A (ja) 2013-05-30
NI201200134A (es) 2012-10-30

Similar Documents

Publication Publication Date Title
CU24133B1 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
LTC3057969I2 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
CO6791605A2 (es) Métodos de tratamiento de trastornos asociados con el fgf21
IL261257B (en) Humanized fc㚚šššššr mice
CU20140025A7 (es) Pirimidinas anilladas sustituidas
GB2579445B (en) Computerized refraction and astigmatism determination
DK2538986T3 (da) Intraartikulært supplement til anvendelse til behandling af ledsygdomme og -skader
IL227193B (en) Plant extracts for the treatment and prevention of infections
ZA201506598B (en) Mice expressing alight chain with human lambda variable and mouse constant regions
CO7190236A2 (es) Métodos para reducir el riesgo de un evento cardiovascular en un sujeto con terapia con estatina
LT3248610T (lt) Fgf21 mutantai ir jų panaudojimas
CO7020878A2 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
GB201113805D0 (en) Interactive lighting effect and wristband
CA144904S (en) Door hinge
LT2726511T (lt) Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui
SE536599C3 (sv) Näringssammansättning med lågt kalori- och lågt proteininnehåll
EP2684167A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES
PT2817329T (pt) Polipeptioos que se ligam ao complemento humano c5
LT2605789T (lt) Modifikuoti relaksino polipeptidai ir jų panaudojimas
GB201213030D0 (en) Improvements in or relating to prosthetics and orthotics
HRP20182046T1 (hr) Uređaj za kuhanje i postupak njegove upotrebe
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
HRP20181276T1 (hr) Konjugat fotosenzibilizatora s hitozanom i njegova upotreba
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej